results the infusion group had a lower plasma pai-1 level compared to the subcutaneous group at day 7 (11.3 ± 1.6 vs. 16.5 ± 4.2; p = 0.003). the urinary ngal level was lower in the infusion group at day 2 (131.3 ± 11.9 vs. 151.2 ± 20.6; p = 0.014); however, at day 7 the ngal level was decreased in the subcutaneous group as much as the infusion group and there was no significant difference betw...

Due to controversial evidence in the literature pertaining to the activity of plasminogen activator inhibitor-1 in platelets, we examined the effects of residual platelets present in plasma (a potential pre-analytical variable) on various plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays. Blood samples were collected from 151 individuals and centrifuged at 3...

Background: To analyze the correlations between plasma coagulation factor VII (FVII), plasminogen activator inhibitor-1 (PAI-1), uric acid, and insulin resistance (IR) diabetic macroangiopathy (DMAP) in elderly patients with type 2 diabetes mellitus (T2DM).

The plasminogen activator inhibitor-1 4G/5G and tissue plasminogen activator Alu-repeat insertion/deletion polymorphisms might be genetic determinations of increased or decreased of their plasma activities. The aim of this study was to investigate the association of plasminogen activator inhibitor-1 4G/5G and tissue plasminogen activator Alu-repeat I/D polymorphisms with metabolic syndrome para...

results a total of 46 patients participated in this study. the significant differences between recovering patients and the patients who died, regarding aspartate aminotransferase (ast), creatine phosphokinase (cpk), lactate dehydrogenase (ldh), prothrombin time (pt), activated partial thromboplastin time (aptt), and thrombocyte and fibrinogen levels, were consistent with many clinical studies i...